Limosilactobacillus Fermentum CRL 1446 - CONICET CASASCO

This research study aims to determine if a probiotic called Limosilactobacillus fermentum CRL 1446 can improve the health of people at risk for cardiovascular disease. The study will be conducted with volunteers who will randomly consume either the probiotic or a placebo (a capsule without the probiotic), without knowing which one they are taking. The researchers will analyze how the probiotic affects blood sugar control, body composition, inflammation, and oxidative stress. The goal is to determine if this beneficial bacterium, by influencing the gut microbiota, could be a new strategy to prevent or mitigate chronic heart diseases.

NCT Number	NCT07530575
Lead Sponsor	PINER Pastor Manfredi Winery Collaborators: National Council of Scientific and Technical Research, Argentina, TIEMPO MEDICO Health Research Center
Conditions	Disbiosis, Obesity, Overweight (BMI > 25), Hypertension (Without Type 2 Diabetes Mellitus), Diabetes (DM), Smoke, Sedentarity, Cholesterol (Total and HDL) +2 more
Enrollment	80 participants
Start Date	2026-02-02
Primary Completion	2027-07-21 (estimated)
Study Completion	2027-07-21 (estimated)
Updated on ClinicalTrials.gov	2026-05-14